The global local anesthesia drugs market size was valued at USD 532 million in 2021 and is anticipated to generate USD 845 million by 2030. The market is projected to grow at a CAGR of 5% during the forecast period (2022–2030). North America is anticipated to hold the largest market share in the global local anesthetic market by generating revenue of USD 1742 million by 2030 at a CAGR of 5% during the forecast period.

New York, United States, July 11, 2022 (GLOBE NEWSWIRE) -- An anesthetic is a drug used to induce temporary numbness or loss of sensation for diagnostic or surgical procedures. Anesthetics are of two types; general anesthetics and local anesthetics. Combinations of anesthetics are also used owing to their additive effects. The anesthetic effect is generally achieved by suppressing the sensory stimulus in the brain and by blocking the conduction of nerves in the nervous system. Local anesthesia is used to numb a particular area of the body without knocking off the conscious as in general anesthesia.

Get a Free Sample Copy of Local Anesthesia Drugs Market Report 

Upcoming Anesthetics, Increasing Surgical, and Postoperative Pain Management Surging Market Growth

The rising number of surgeries, especially due to accidents and chronic ailments like cardiovascular diseases, cancers, and orthopedic disorders, are driving the growth of the global local anesthesia drugs market. In addition, the number of injuries requiring medical attention has also increased. As per the data published by the National Safety Council of the United States, about 4.4 million people were injured seriously enough to require medical attention in crashes in 2019.

Additionally, the number of cesarean deliveries is on the rise all over the globe, which is also expected to drive market growth. Bupivacaine is the most common local anesthetic used in spinal anesthesia for cesarean delivery. Hence, the increasing C-sections worldwide are boosting the demand for local anesthetic drugs. Hence, the increasing number of surgeries and increasing demand for local anesthetic drugs are expected to drive market growth over the forecast period.

Accelerating research and development investments in the identification and development of new local anesthetic drugs and subsequent new product approvals by regulatory bodies is expected to be one of the major factors for the growth of the market in the coming years. In August 2020, Amneal Pharmaceuticals Inc. received the Abbreviated New Drug Application (ANDA) approval from the US Food and Drug Administration (FDA) for a generic version of Lidocaine Patch 5%. Therefore, the new approvals for local anesthetic drugs and frequent product launches boost the demand for drugs, increase R&D programs and funding, and boost market growth over the forecast period.

With the increasing number of surgeries globally, the need for local anesthetic drugs is expected to surge. Local anesthetics (LAs) are commonly infiltrated into surgical wounds for postsurgical analgesia. Effective surgical pain control is an important treatment goal to reduce morbidity and improve faster return to activity and work. It is also an important patient-centered outcome and an important factor in patient satisfaction and quality of life.

Additionally, as per the research article published in JAMA Network in 2021, a study was conducted to determine whether liposomal bupivacaine would improve the intensity and duration of postoperative pain in major truncal surgery as it has been reported to do in other nontruncal orthopedic, cosmetic, and colorectal indications and whether it could also reduce reliance on opioid medications.

The study revealed a significant reduction in pain and opioid use over three postoperative days and found that the Numerical Rating Scale (NRS) scores were reduced at a faster rate in patients treated with bupivacaine hydrochloride. Thus, owing to the increasing benefits of local anesthetic in reducing postoperative pain, the studied market is expected to witness significant growth over the forecast period.

Impact of COVID-19

Currently, all the countries across the globe faced the outbreak of COVID-19. Many pharmaceutical and biotechnological companies are constantly focusing their R&D investments on the production of antiseptic products and preventive vaccines to suffice the demand of customers. During the initial stages of the lockdown, trades were suspended with other countries owing to travel restrictions.

The usage of local anesthesia for treating patients with COVID-19 is in high demand due to its negligible risk of viral transmission. The healthcare system implemented changes in the procedure or practice to contain the infection to the workers and patients in the medical facilities. Regional anesthesia generally maintains respiratory functions and circumvents airway instrumentation, further helping to limit viral transmission, thus making it mandatory to maintain under regional anesthesia as far as possible. However, elective and crucial surgeries have resumed gradually after the lift of lockdown and restrictions. Nerve blocking procedures are planned to be conducted in special and well-prepared operative rooms, which helps in reducing the risk of infection.

In addition, the adoption of regional anesthesia mitigates adverse effects during the postoperative period. It ensures safety for patients and teams. Therefore, due to the advantages offered by local anesthesia over general anesthesia, the local anesthesia drugs market is anticipated to experience significant growth during the pandemic. However, due to the reduced elective surgeries, local anesthetic drugs for non-COVID-19 indications can be impacted.

Buy Now @ https://straitsresearch.com/buy-now/local-anesthesia-drugs-market 

Regional Analysis of Global Local Anesthesia Drugs Market

North America is anticipated to hold the largest market share in the global local anesthetic market by generating revenue of USD 1742 million by 2030 at a CAGR of 5% during the forecast period. The market in North America was valued at USD 1099 million in 2021. The major factors contributing to the rising market share are the sudden increase in the number of surgeries conducted, the increasing old age population, and the increasing number of people with chronic health conditions. Europe is the second contributor to the local anesthesia drugs market, with revenue of USD 678 million in 2021. Owing to an increase in dental procedures, advancements in medical science, number of surgeries related to cardiovascular ailments, orthopedics, hernia, and other ailments, the market for anesthetic drugs is anticipated to grow exponentially in this region. 

The local anesthetic drugs market in Asia-Pacific is expected to witness steady growth with USD 615 million in 2021. The increasing cases of chronic diseases, rising number of surgical approaches, load of the aging population, and related diseases increasing the procurement of local anesthetics for surgery and management of postoperative pain are the factors expected to drive the market growth. South America and Middle East & Africa have the lowest market owing to post pandemic effects and slow growing healthcare facilities.

Report Scope:

Report Metric	Details
Market Size	USD  845 Million by 2030
CAGR	5% (2022-2030)
Historical Data	2019-2020
Base Year	2021
Forecast Period	2022-2030
Forecast Units	Value (USD Million)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Drug Type, Mode of Administration and Geography
Geographies Covered	North America, Europe, Asia-Pacific, LAME and Rest of the World
Key Companies Profiled/Vendors	Hikma Pharmaceuticals PLC, Fresenius SE & Co. KGaA, Glenmark Pharmaceutical Ltd, Braun Melsulgen AG, Pacira BioSciences Inc., Pfizer Inc, Septodont, Teva Pharmaceutical Industries Limited.
Key Market Opportunities	Increasing Technological Advancements Creating New Growth Avenues
Key Market Drivers	Increase in Surgeries Surging Global Local Anesthesia Drugs Market Growth Approval of Upcoming Anesthetics Boosting Market Growth

Key Highlights:

• The global local anesthesia drugs market was valued at USD 532 million in 2021 and is anticipated to generate USD 845 million by 2030. The market is projected to grow at a CAGR of 5% during the forecast period (2021–2030).
• Based on drug type, lidocaine is the major shareholder in the global local anesthesia drugs market. The segment is projected to generate USD 1343 million in 2030 and grow at a CAGR of 5% by 2030.
• By the mode of administration, global local anesthesia drugs market is segmented as injectable and surface anesthetic. Injectable drug is the highest market shareholder. The injectable anesthetics segment is projected to generate USD 3693 million in 2030 and grow at a CAGR of 5% by 2030.
• Geographically, the market is divided into North America, Europe, Asia-Pacific, Central and South America, and the Middle East and Africa. The market in North America is valued at USD 1742 million by 2030 at a CAGR 5% during the forecast period.

Get a Free Sample Copy of This Report @  https://straitsresearch.com/report/local-anesthesia-drugs-market/request-sample 

The key players in the local anesthesia drugs market are

• Hikma Pharmaceuticals PLC
• Fresenius SE & Co. KGaA
• Glenmark Pharmaceutical Ltd
• B. Braun Melsulgen AG
• Pacira BioSciences Inc.
• Pfizer Inc
• Septodont
• Teva Pharmaceutical Industries Limited

Global Local Anesthesia Drugs Market - Segmentation

By Drug Type

• Bupivacaine
• Lidocaine
• Benzocaine
• Ropivacaine
• Prilocaine
• Chloroprocaine
• Others

By Mode of Administration

• Injectable
• Surface Anesthetic

By Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East &Africa

TABLE OF CONTENT

1          Introduction

1.1      Market Definition

1.2      Market Scope

2          Research Methodology

2.1      Primary Research

2.2      Research Methodology

2.3      Assumptions & Exclusions

2.4      Secondary Data Sources

3          Executive Summary

4          Market Overview

4.1      Report Segmentation & Scope

4.2      Value Chain Analysis: Local Anesthesia Drugs Market

4.2.1  Vendor Matrix

4.3      Key Market Trends

4.3.1  Drivers

4.3.2  Restraints

4.3.3  Opportunities

4.4      Porter’s Five Forces Analysis

4.4.1  Bargaining Power of Suppliers

4.4.2  Bargaining Power of Buyers

4.4.3  Threat of Substitution

4.4.4  Threat of New Entrants

4.4.5  Competitive Rivalry

4.5      Environment & Regulatory Landscape

4.6      Forecast Factors & Relevance of Impact

4.7      Macro-Economic & Geopolitical Scenario

4.8      Parent Market Overview

4.9      Technology Landscape

4.10   Market Share Analysis

4.11   Potential Venture Analysis

4.12   Regional Price Trends

4.13   Raw Material Trends

4.14   Cost Structure Analysis

4.14.1 Labor Cost

4.14.2 Consumables

4.14.3 Maintenance Cost

4.15   Covid-19 Impact Analysis:

4.15.1 Pre and Post Covid-19 Market Scenario Analysis

4.15.2 Market Recovery Timeline and Challenge

4.15.3 Measures Taken by Top Players

4.15.4 Quarterly Market Revenue and Growth Forecast till 2021

4.15.4.1        North America

4.15.4.2        Europe

4.15.4.3        Asia-Pacific

4.15.4.4        Central and South America and the Caribbean

4.15.4.5        The Middle East and Africa

5           Drug Type Overview

5.1      Introduction

5.1.1  Market Size & Forecast (Value & Volume)

5.2      Bupivacaine

5.2.1  Market Size & Forecast (Value & Volume)

5.3      Lidocaine

5.3.1  Market Size & Forecast (Value & Volume)

5.4      Benzocaine

5.4.1  Market Size & Forecast (Value & Volume)

5.5      Ropivacaine

5.5.1  Market Size & Forecast (Value & Volume)

5.6      Prilocaine

5.6.1  Market Size & Forecast (Value & Volume)

5.7      Chloroprocaine

5.7.1  Market Size & Forecast (Value & Volume)

5.8      Others

5.8.1  Market Size & Forecast (Value & Volume)

6          Mode of Administration Overview

6.1      Introduction

6.1.1  Market Size & Forecast (Value & Volume)

6.2      Injectable

6.2.1  Market Size & Forecast (Value & Volume)

6.3      Surface Anesthetic

6.3.1  Market Size & Forecast (Value & Volume)

7          Regional Overview

7.1      Introduction

7.1.1  Market Size & Forecast (Value & Volume)

7.2      North America

7.2.1  Economic Overview

7.2.2  Market Scenario

7.2.3  U.S.

7.2.4  Canada

7.2.5  Mexico

7.3      Central and South America and the Caribbean

7.3.1  Economic Overview

7.3.2  Market Scenario

7.3.3  Brazil

7.3.4  Argentina

7.3.5  Colombia

7.3.6  Rest of Central and South America and the Caribbean

7.4      Europe

7.4.1  Economic Overview

7.4.2  Market Scenario

7.4.3  Germany

7.4.4  France

7.4.5  The U.K.

7.4.6  Italy

7.4.7  The Rest Of Europe

7.5      Asia-Pacific (APAC)

7.5.1  Economic Overview

7.5.2  Market Scenario

7.5.3  China

7.5.4  Japan

7.5.5  India

7.5.6  Australia

7.5.7  South Korea

7.5.8  Rest Of APAC

7.6      Middle East

7.6.1  Economic Overview

7.6.2  Market Scenario

7.6.3  South Arabia

7.6.4  The UAE

7.6.5  Qatar

7.6.6  Oman

7.6.7  Turkey

7.6.8  The Rest Of Middle East

7.7      Africa

7.7.1  Economic Overview

7.7.2  Market Scenario

7.7.3  Nigeria

7.7.4  South Africa

7.7.5  The Rest Of Africa

8          Competitive Landscape — Manufacturers & Suppliers

8.1      Competition Dashboard

8.2      Industry Structure

8.3      Hikma Pharmaceuticals PLC

8.3.1  Business Overview

8.3.2  Financial Performance

8.3.3  Recent Developments

8.3.4  Portfolio

8.4      Fresenius SE & Co. KGaA

8.5      Glenmark Pharmaceutical Ltd

8.6      B. Braun Melsulgen AG

8.7      Pacira BioSciences Inc.

8.8      Pfizer Inc

8.9      Septodont

8.10   Teva Pharmaceutical Industries Limited

9          Conclusion & Recommendation

10       Acronyms & Abbreviations

Read the full Report Description with Table of Content and Figure @ https://straitsresearch.com/report/local-anesthesia-drugs-market/toc 

Market News:

• In December 2020, Hikma Pharmaceuticals PLC Ropivacaine HCl Injection, USP 40mg/20mL in the United States indicated the production of local or regional anesthesia for surgery and acute pain management through its US affiliate Hikma Pharmaceuticals USA Inc.
• In November 2020, Pfizer announced the completion of merging its Upjohn business with Mylan N.V. to form Viatris Inc., where Pfizer would hold 57% of the shares of the company.
• In August 2020, Teva Pharmaceuticals announced a strategic partnership with a biopharmaceutical company called Alvotech for the commercialization of five biosimilar products in the United States.
• In August 2020, B. Braun and Royal Philips announced that their Onvision needle tip tracking technology for regional anesthesia got the 501(k) clearance from the United States Food and Drug Administration.
• In January 2020, Pacira BioSciences announced a collaboration with Envision Physician Services to train anesthesiology clinicians on ultrasound-guided regional anesthesia techniques.
• In June 2019, Fresenius Medical Care announced the acquisition of NxStage Medical, Inc. after approval from authorities in the United States.
• In February 2019, Glenmark announced the spin-off of its innovative business into a new company in the United States after the approval from its Board of Directors.

News Media

Top 7 Asia-Pacific Pharma Companies Developing COVID19 Vaccine

Coronavirus Crisis - Impact Of COVID-19 On Healthcare Industry

How AI Is Laying The Foundation In The Discovery Of Drugs?

Have a Look at the Related Research Report

Isoxazoline Drugs Market: Information by Product Type (Fluralaner, Sarolaner, Lotilaner, and Afoxolaner), Pet Type (Dogs and Cats), and Region — Forecast till 2030

Anti-HIV Drugs Market: Information by Medication Class (Nucleoside Reverse Transcriptase Inhibitors (NRTIS)), Distribution Channel (Hospital Pharmacies), Region — Forecast till 2029

Multiple Sclerosis Drugs Market: Information by Drug Class (Immunomodulator, Immunosuppressant, Interferons), Route of Administration (Oral, Injectable), and Region — Forecast till 2029

Veterinary Pharmaceutical Drugs Market: Information by Disease (Swine Influenza, Osteoarthritis, Newcastle Disease), Drug Types (Swine Drug, Poultry Drug), and Region — Forecast till 2027

Veterinary Dermatology Drugs Market: Information by Drug (Antibiotics, Veterinary Antifungal Drugs), Animal Type (Large & Small Animals), End Users (Veterinary Hospitals)—Forecast Till 2026

Tuberculosis (TB) Drugs Market: Information by Disease Type (Active TB, Latent TB), Therapy (First-Line, Second-Line) and Regional Outlook - Forecast Till 2026

About Straits Research Pvt. Ltd.

StraitsResearch is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.

Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.

For more information on your target market, please contact us below:

Phone: +1 646 480 7505 (the U.S.)

+91 8087085354 (APAC)

+44 208 068 9665 (the U.K.)

Email: sales@straitsresearch.com

Follow Us: LinkedIn | Facebook | Instagram | Twitter

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.